- Details
- Neeraj Agarwal delves into two ground-breaking studies, discussing the importance of ctDNA testing and the clinical implications of SPOP mutations in patients with metastatic prostate cancer. The first study, led by Dr. Kim Chi, demonstrates that ctDNA testing is a viable alternative to invasive tissue testing, particularly in detecting BRCA and ATM mutations. CtDNA tests showed impressive sensiti...
|
- Details
- Jeffrey Ross speaks about the evolution and application of liquid biopsies in cancer treatment, including in cases of advanced metastatic breast cancer and prostate cancer. Drawing from his experience with circulating cancer cells, he details the development of circulating DNA and emphasizes the importance of precision medicine and personalized care. He contrasts liquid biopsies with tissue biopsi...
|
- Details
- Samuel Washington shares insights from a study analyzing treatment practices for metastatic prostate cancer across the US. Utilizing a broad dataset provided by ConcertAI, a data warehouse company focusing on AI and big data, the team investigated patterns of doublet therapy administration among patients diagnosed with M1 disease. Dr. Washington and his team identified over 1,700 men across the co...
|
- Details
- Charles Ryan and Clayton Yates delve into the intricate landscape of health disparities and global health equity. Central to the discussion is Dr. Yates's groundbreaking work as principal investigator of MET-PAAM, studying the molecular mechanisms of tumor progression in metastatic prostate cancer among men of African descent. Dr. Yates provides insights into the unique BRCA2 gene variants found i...
|
- Details
- Martin Sjöström discusses his groundbreaking research on liquid biopsy biomarkers in prostate cancer. Dr. Sjöström’s team is developing a platform that uses the epigenetic modification, 5-hydroxymethylcytosine (5hmC), found in cell-free DNA circulating in the blood, to predict a patient's response to therapy and detect treatment resistance earlier. The novel approach provides broader and more comp...
|
- Details
- Alicia Morgans and Emmanuel Antonarakis discuss an ongoing biomarker analysis aimed at identifying a molecular signature predictive of response in the COMBAT study. The COMBAT study is a multi-center, single-arm, open label Phase 2 study in asymptomatic patients with mCRPC who had soft tissue metastases amenable to biopsy, and who progressed on at least one prior novel AR-targeted therapy (and up...
|
- Details
- Alicia Morgans converses with Neeraj Agarwal about the ongoing phase III Contact-02 Trial, designed for patients with metastatic castrate-resistant prostate cancer (CRPC) who show disease progression on a novel hormonal therapy or androgen receptor inhibitor. Patients eligible for this trial should have measurable disease, which may include extra pelvic lymphadenopathy or visceral metastasis. Dr....
|
- Details
- In this discussion, Neal Shore speaks with Alicia Morgans to discuss their experiences and insights on topics ranging from survivorship to new developments in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Dr. Morgans highlights her work in the EAU session on mCRPC, outlining the significance of PARP inhibitors, the PROpel and MAGNITUDE trials, and the potential role of...
|
- Details
- Rahul Aggarwal speaks with Alicia Morgans about the completed phase III trial AFT-19 for high-risk biochemically relapsed prostate cancer patients. The trial explored three arms: ADT alone, ADT plus apalutamide, and a triplet of ADT, apalutamide, and abiraterone, with a primary endpoint of PSA progression-free survival. Results showed significant prolongation of PSA progression-free survival in bo...
|
- Details
- In this discussion, Susan Slovin and Alicia Morgans discuss the incorporation of PSMA PET imaging and emerging treatments like lutetium-177-PSMA in genitourinary oncology. Referencing ASCO 2022 talks and clinical trials, particularly Dr. Mike Hofman's study comparing lutetium-PSMA and cabazitaxel post-docetaxel, they review three-year data showing no significant difference in overall survival betw...
|
